Preventive Cardiology Digest

Both sources emphasize shifting from fixed LDL numbers to plaque burden for true risk assessment.

• Podcast argues zero plaque means near-zero event...

Hypertriglyceridemia updates and secondary prevention debates converge on addressing residual risk beyond LDL.

• TG elevations raise CVD risk through...

Modest concurrent improvements across sleep, moderate-to-vigorous physical activity and diet quality were linked to a 57% lower risk of MACE in a...

Merck's engineered-enzyme synthesis slashes enlicitide production steps by more than half while delivering 39% yield at multi-kilogram scale,...

No significant updates today.

No significant updates today.

• Single-dose VERVE-102 produced up to 62% LDL-C and 88% PCSK9 reductions, durable for 18 months.
• Lilly's $1B Verve acquisition gains momentum as...

Lp(a) is a potent, mostly genetic risk factor for heart disease that affects roughly 1 in 5 adults and is more strongly linked to events than LDL in...

• LDL targets clarified: New <55 mg/dL goal for very high-risk patients now appears in patient charts alongside statin options
• Risk tools updated:...

Early LDL Lowering Benefits

• 🔥 Lowering LDL Earlier Prevents More Events: Imperial College analysis shows reducing LDL by 0.36 mmol/litre in...

Three recent Atherosclerosis papers chart a decisive move toward risk-based lipid care.

• Network medicine integrates multi-omic and imaging data...

Early trial results suggest a single infusion of a revolutionary therapy could significantly lower bad cholesterol for life, fueling media excitement over potential one-time treatment.

Is intensive blood pressure lowering always the right call for adults over 75?

• Aggressive targets may raise risks of falls, dizziness, fainting,...

Reducing LDL by just 0.36 mmol/L early in lower-risk patients cuts long-term cardiac events by 25%, while achieving the same benefit later in...

VERVE-102 delivered 62% LDL reduction at the highest dose, sustained up to 18 months, matching PCSK9 inhibitors while offering permanent PCSK9 gene...

Most Part D plans cover Repatha but place it on Tier 3–5 with prior authorization required.

• Verify formulary first: Coverage reaches ~95% of plans...

New Trial Designs

• IMPACS Post-STEMI Study: National prospective multicentre study evaluating standardized intensified outpatient secondary...

Calcific aortic valve stenosis (CAVS) affects 9.6–12.6 million people worldwide and causes over 100,000 deaths annually, with burden expected to grow...

Global Lp(a)-lowering trials are advancing rapidly, with pelacarsen results from Lp(a)HORIZON expected late 2026 and multiple siRNA and oral agents in...

• SPISE index paired with ensemble machine learning refines cardiovascular risk assessment
• Acute-phase IL-6 and SAA show association with...